

May 27, 2023

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Re: Information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of Aurobindo Pharma Limited (the "Company") at its meeting held today i.e. May 27, 2023, has approved sale and transfer of all equity shares held by the Company in Auro Vaccines Private Limited, a wholly owned subsidiary of the Company, to Curateq Biologics Private Limited, another wholly owned subsidiary of the Company, as part of verticalization of business operations.

Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, for sale or disposal of unit(s) or division(s) or subsidiary of the listed entity are provided at **Annexure-"A"**,

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500 038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure – A

Sl.No	Particulars	Response
1	Date on which the agreement for sale has been entered into	May 27, 2023. As per the Share Purchase Agreement, the entire equity share capital of Rs. 10,00,000 (divided into 1,00,000 equity shares of Rs.10 each) of Auro Vaccines Private Limited, a wholly owned subsidiary of the Company incorporated on November 8, 2021, will be transferred by the Company to Curateq Biologics Private Limited, another wholly owned subsidiary of the Company. The agreement will be entered into among the Company as a seller, Curateq Biologics Private Limited as a buyer and Auro Vaccines Private Limited as a target company.
2	The expected date of completion of sale/disposal	The completion of the sale is estimated in the first quarter of FY 2023-24
3	Consideration received from such sale/disposal	The shares are proposed to be transferred at par and accordingly, the consideration is Rs. 10 lakhs for transfer of 1,00,000 equity shares of Rs.10 each.
4	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Curateq Biologics Private Limited ("Curateq"), the Buyer, is a wholly owned subsidiary of Aurobindo Pharma Limited and does not belong to the promoter/promoter group/group companies.
5	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"	Curateq being a wholly owned subsidiary of the Company, the two are related parties as per Regulation 2 (zb) of SEBI (Listing at Obligations and Disclosure Requirements) Regulations, 2015. The transaction is being undertaken between the holding company and its wholly owned subsidiary and accordingly there is no impact on a consolidated basis. As per provisions of Section 188 of Companies Act, 2013 and Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provisions relating to related party transactions are not applicable in respect of transactions between holding company and its wholly owned subsidiary.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivi, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com